Amethyst & Stingray Announce Cancer Care Alliance

Amethyst Healthcare has announced a strategic alliance with European oncology network Stingray Healthcare, based in Lausanne, Switzerland, a move that will see the biggest independent cancer care platform created.

The new partnership will see patient access expanded to high-quality cancer care across Europe, with over 30 treatment centres across eight countries in operation and approximately 35,000 radiotherapy treatments delivered annually via linear accelerators (which customise electrons or high-energy X-rays to conform to tumour shapes, targeting cancer cells without damaging the surrounding healthy tissue).

Stingray already has established a strong presence in both France and Germany, the two biggest radiotherapy markets in Europe, while Amethyst has radiotherapy treatment centres in France, Poland, Romania, the UK, Austria, Portugal and Italy. 

Both organisations will maintain their local identities, while sharing expertise and best practices to continue delivering world-class care.

Commenting on the news, Ralph Hefti – founding CEO of Stingray and incoming CEO of the allied group – said: “This marks a pivotal moment for our teams and patients across Europe. 

“By combining the complementary strengths of Stingray and Amethyst, we are creating a truly pan-European platform with the scale and capability to transform cancer care. Together, we are uniting outstanding clinicians, cutting-edge technology and a shared vision to make high-quality oncology treatment more accessible to patients everywhere.”

This strategic alliance follows the acquisition of Stingray by investment firm Fremman Capital. 

Fremman’s founding partner, Edward Chandler, described the move as a “transformational moment for cancer care in Europe”, adding that it will create the scale, quality and reach required to improve patient access to innovative oncology treatment in Europe.